Skip to main content

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 190
  • Page 191
  • Page 192
  • Page 193
  • Page 194
  • Page 195
  • Page 196
  • Page 197
  • Page 198
  • …
  • Next page Next
  • Last page Last
Subscribe to